Wada Daiki, Nakamori Yasushi, Maruyama Shuhei, Shimazu Haruka, Saito Fukuki, Yoshiya Kazuhisa, Kuwagata Yasuyuki
Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, 10-15 Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan.
Department of Emergency and Critical Care Medicine, Kansai Medical University Hospital, 2- 3-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Exp Hematol Oncol. 2022 Sep 9;11(1):53. doi: 10.1186/s40164-022-00307-9.
Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to viral escape phenomena. Highly efficacious antiviral therapies in immunosuppressed hosts with COVID-19 are urgently needed. From February 2022, we introduced novel treatment combining antiviral therapies and neutralizing antibodies with frequent monitoring of spike-specific antibody and RT-PCR cycle threshold (Ct) values as indicators of viral load for immunocompromised patients with persistent COVID-19 infection. We applied this treatment to 10 immunosuppressed patients with COVID-19, and all completed treatment without relapse of infection. This may be a potentially successful treatment strategy that enables us to sustain viral clearance, determine optimal timing to stop treatment, and prevent virus reactivation in immunocompromised patients with persistent COVID-19.
由于免疫功能低下患者中越来越多地认识到严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的长期病毒复制，亚急性或慢性冠状病毒病（COVID-19）肺炎可导致持续性肺损伤，并可能导致病毒逃逸现象。迫切需要为患有COVID-19的免疫抑制宿主提供高效的抗病毒治疗。自2022年2月起，我们引入了一种新的治疗方法，将抗病毒治疗和中和抗体相结合，并频繁监测刺突特异性抗体和逆转录聚合酶链反应（RT-PCR）循环阈值（Ct）值，作为持续性COVID-19感染免疫功能低下患者病毒载量的指标。我们将这种治疗方法应用于10例患有COVID-19的免疫抑制患者，所有患者均完成治疗且未出现感染复发。这可能是一种潜在成功的治疗策略，使我们能够维持病毒清除，确定停止治疗的最佳时机，并防止持续性COVID-19免疫功能低下患者的病毒重新激活。
